In the massive undertaking of work that is the response to the COVID-19 pandemic, the US National Institutes of Health has employed the tremendous data generated by its vast network of patients and is driving forward the effort to accurately predict the effectiveness of specific therapeutic agents, based on their genetic makeup, in order to test and refine them.
This work is centered on cancer cancers of the blood, on early stage disease, and suggests that it may be possible to merge computer models based on genetic information with cell sources for clinicians directly assessing phenotypes of drugs, with a view towards more accurate cancer prognosis.
Thus, GIS-enabled analyses may be helpful in the many dimensions of this problem, and also may help to predict the outcomes of tests or drug development.
To the broad public, it is probably beneficial that we create thorough descriptions in which all the critical aspects of this domain are clearly and simultaneously represented.